NAMS Insider Trading Activity and SEC Form 4 Filings
NAMS insider trading summary
Over the past 12 months, insiders at NewAmsterdam Pharma Co N.V. (NAMS) reported 38 sales worth $58.0M by 5 insiders and 1 open-market purchase worth $227K by 1 insider on SEC Form 4. Net insider selling was $57.8M.
Latest NAMS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Sell | $1.3M (50,246 @ $25.03) |
| Sep 14, 2026 | Michael H. Davidson | Chief Executive Officer | Buy | $227K (10,000 @ $22.65) |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Sell | $3.4M (125,000 @ $26.91) |
| Jul 20, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sell | $2.1M (70,200 @ $29.96) |
| Jul 20, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sell | $990K (31,885 @ $31.05) |
| Jul 20, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sell | $92K (2,915 @ $31.71) |
| Jun 22, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sell | $9K (300 @ $30.73) |
| Jun 22, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sell | $1.2M (39,700 @ $30.20) |
| May 26, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sell | $2.3M (65,000 @ $35.69) |
| Mar 11, 2026 | Louis G Lange | Insider | Sell | $1.3M (44,173 @ $30.41) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.